Study for the effects of once-daily semaglutid on glycemic control in patients with type 2 diabetes (SWITCH SEMA-2 study)

Phase 4

Recruiting

• Conditions: type 2 diabetes

• Registration Number: JPRN-jRCT1011210032
• Lead Sponsor: omoto Hiroshi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

1) Age 20-90 years old
2) HbA1c 7.0-10.0%
3) BMI >= 18.5 kg/m2
4) patients who were treated with DPP-4 inhibitors at least for 12 weeks without discontinuation for more than 1 week (SItagliptin, teneligliptin, and anagliptin: from regular dose to maximun dose; vildagliptin, saxagliptin, trelagliptin, linagliptin, alogliptin, and omarigliptin: regular dose)
5) written informed consent

Exclusion Criteria

1) treatment with GLP-1 receptor agonists within past 12 weeks
2) history of anaphylaxis of semaglutide
3) unstable retinopathy
4) severe hepatic dysfunction or renal dysfunction
5) severe ketosis, diabetic coma
6) severe infection, surgery, serious trauma
7) female patients who are pregnant, lactating and/or willing to be pregnant, or male patients who wants to impregnate partner during study period
8) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Study & Design

• Study Type: Interventional
• Study Design: Not specified